Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability study of linerixibat for cholestatic pruritus in primary biliary cholangitis
MOH_2023-03-09_012416Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of linerixibat in cholestatic pruritus, sponsored by GSK. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritus
Beyond the preview
Go deeper on MOH_2023-03-09_012416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-09_012416.